Recent News

• 06.06.2025 - New THRIVE Data Demonstrates Penumbra’s CAVT™ Technology Is Associated with Reduced Related Readmissions and Complication Rates When Managing ALI
• 06.05.2025 - Penumbra’s Ruby XL System Cleared by FDA for Peripheral Embolization
• 06.05.2025 - Penumbra Introduces the Ruby® XL System – the Longest, Largest, and Softest Coil on the Market for Vascular Embolization
• 05.29.2025 - Employee Spotlight: Maria R. Contreras
• 05.20.2025 - Penumbra, Inc. to Present at Upcoming Investor Conferences
• 05.12.2025 - Trial Finds Penumbra’s RED 43 Aspiration Catheter Safe and Effective for Thrombectomy of Distal Medium Vessel Occlusions in Acute Ischemic Stroke
• 05.08.2025 - How Stroke Survivors Are Thriving with Advanced Care
• 05.07.2025 - Penumbra Launches STRIDE II Clinical Study to Further Evaluate Penumbra’s CAVT Technology for Lower Extremity Acute Limb Ischemia

Recent Filings

• 06.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.30.2025 - 8-K Current report
• 05.30.2025 - SD Specialized disclosure report
• 05.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.28.2025 - 144 Report of proposed sale of securities
• 05.22.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2025 - 144 Report of proposed sale of securities
• 05.14.2025 - 4 Statement of changes in beneficial ownership of securities